Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 8/20 | 0.57 |
| ▸ | MC4R | P32245 | 2/20 | 0.37 |
| ▸ | MC5R | P33032 | 2/20 | 0.37 |
| ▸ | MC3R | P41968 | 2/20 | 0.37 |
| ▸ | TACR1 | P25103 | 2/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4294251 | 1.00 | GHSR (0.57) | GHSRMC4RMC5RMC3RTACR1 | |
| SCHEMBL3267246 | 0.86 | GHSR (0.50) | GHSRTACR1MMP9MMP8 | |
| SCHEMBL3267249 | 0.86 | GHSR (0.50) | GHSRTACR1MMP9MMP8 | |
| SCHEMBL6319064 | 0.83 | GHSR (0.49) | GHSRTACR1SIGMAR1 | |
| SCHEMBL6319068 | 0.83 | GHSR (0.49) | GHSRTACR1SIGMAR1 | |
| SCHEMBL10039191 | 0.82 | GHSR (0.46) | GHSRTACR1 | |
| SCHEMBL1401016 | 0.82 | GHSR (0.46) | GHSRTACR1 | |
| SCHEMBL1401013 | 0.82 | GHSR (0.46) | GHSRTACR1 | |
| SCHEMBL867608 | 0.81 | GHSR (0.45) | GHSRTACR1 | |
| SCHEMBL7896416 | 0.81 | GHSR (0.45) | GHSRTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10039813-B2 | Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-08-07 | — | — | US | disclosed |
| US-9821042-B2 | Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-11-21 | — | — | US | disclosed |
| US-20160106821-A1 | FUNCTIONAL GHRELIN RECEPTOR ANTAGONISM DURING PREGNANCY TO PREVENT STRESS-ASSOCIATED MENTAL ILLNESS IN OFFSPRING AND MOTHERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-04-21 | — | — | US | disclosed |
| US-20160058851-A1 | USE OF ANTAGONISTS OF GHRELIN OR GHRELIN RECEPTOR TO PREVENT OR TREAT STRESS-SENSITIVE PSYCHIATRIC ILLNESS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-03-03 | — | — | US | disclosed |
| US-20150297691-A1 | USE OF ANTAGONISTS OF GHRELIN OR GHRELIN RECEPTOR TO PREVENT OR TREAT STRESS-SENSITIVE PSYCHIATRIC ILLNESS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-10-22 | — | — | US | disclosed |
| WO-2013119800-A1 | USE OF ANTAGONISTS OF GHRELIN OR GHRELIN RECEPTOR TO PREVENT OR TREAT STRESS-SENSITIVE PSYCHIATRIC ILLNESS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-08-15 | — | — | WO | disclosed |
| US-20090149512-A1 | Use of Ghrelin Antagonists to the Treatment of Certain CNS Diseases | NOVO NORDISK A/S (DK) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149512-A1 | Use of Ghrelin Antagonists to the Treatment of Certain CNS Diseases | GIPR, GHSR, GPR119 | GHSR 2/4885MC4R 8/4885MC5R 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.